Advances in Aerobic Exercise for Pulmonary Arterial Hypertension: Mechanisms of Action and Clinical Insights
- 1Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha 410011, China
- 2Department of Nutrition, The Second Xiangya Hospital of Central South University, Changsha 410011, China
Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary artery pressure and pulmonary vascular resistance, leading to right heart failure and death in severe cases. PAH is classified as Group 1 pulmonary hypertension (PH). Although Groups 2 and 3 PH are more common, this review focuses primarily on PAH. Currently, there are three main classes of targeted drugs in clinical practice, and their main mechanism is to dilate pulmonary artery vessels. These drugs can delay the progression of PAH and improve the quality of life. However, the long-term prognosis is still not optimistic. At present, patients with PAH still need a multi-drug combination and comprehensive treatment. Aerobic exercise, as a non-pharmacological adjunctive therapy, is believed to have a positive impact on PAH treatment when performed regularly in patients with stable conditions. With the widespread application of aerobic exercise in the treatment of cardiovascular diseases, increasing research is exploring its potential in adjunctive therapy for PAH. Studies suggest that exercise-based rehabilitation incorporating aerobic exercise, when added to optimized PAH-targeted therapy, may improve exercise capacity, quality of life, and selected cardiopulmonary or hemodynamic parameters in clinically stable patients with PAH. However, evidence for reversal of pulmonary vascular remodeling or mortality benefit remains limited. This review summarizes the clinical evidence and mechanisms of aerobic exercise specifically in PAH.
Related
- Mechanisms and Advances in the Treatment of Arrhythmias Associated With Pulmonary Hypertension
- The Functional Molecular Biopsy: Exercise-Induced Transpulmonary Multi-Omic Profiling in Pulmonary Arterial Hypertension
- Advances in Mechanisms and Management Strategies of Pulmonary Hypertension: A Review
- Endothelial Redox Dysregulation in Pulmonary Arterial Hypertension: Compartmentalized Mechanisms and Therapeutic Implications
- Bile acid dysregulation in pulmonary arterial hypertension: strengthening the liver-lung axis in pulmonary vascular disease
BibTeX
@article{wang2026advances,
title = {{Advances in Aerobic Exercise for Pulmonary Arterial Hypertension: Mechanisms of Action and Clinical Insights}},
author = {Tianyu Wang and Yingjie Tan and Limin Deng and Jiang Li},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207960},
url = {https://www.mdpi.com/2077-0383/15/20/7960},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Advances in Aerobic Exercise for Pulmonary Arterial Hypertension: Mechanisms of Action and Clinical Insights
AU - Tianyu Wang
AU - Yingjie Tan
AU - Limin Deng
AU - Jiang Li
PY - 2026
DA - 2026/10/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207960
UR - https://www.mdpi.com/2077-0383/15/20/7960
AB - Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary artery pressure and pulmonary vascular resistance, leading to right heart failure and death in severe cases. PAH is classified as Group 1 pulmonary hypertension (PH). Although Groups 2 and 3 PH are more common, this review focuses primarily on PAH. Currently, there are three main classes of targeted drugs in clinical practice, and their main mechanism is to dilate pulmonary artery vessels. These drugs can delay the progression of PAH and improve the quality of life. However, the long-term prognosis is still not optimistic. At present, patients with PAH still need a multi-drug combination and comprehensive treatment. Aerobic exercise, as a non-pharmacological adjunctive therapy, is believed to have a positive impact on PAH treatment when performed regularly in patients with stable conditions. With the widespread application of aerobic exercise in the treatment of cardiovascular diseases, increasing research is exploring its potential in adjunctive therapy for PAH. Studies suggest that exercise-based rehabilitation incorporating aerobic exercise, when added to optimized PAH-targeted therapy, may improve exercise capacity, quality of life, and selected cardiopulmonary or hemodynamic parameters in clinically stable patients with PAH. However, evidence for reversal of pulmonary vascular remodeling or mortality benefit remains limited. This review summarizes the clinical evidence and mechanisms of aerobic exercise specifically in PAH.
SN - 2077-0383
ER -